Enbrel (etanercept) approved for the treatment of adult patients with chronic moderate to severe plaque psoriasis

Article

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--April 30 ? Amgen Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced Friday that Enbrel (etanercept) has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.